PCBL Chemical Limited has informed the Exchange regarding 'Financial Results for the period ended 31st March, 2025.'.
PCBL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Smallcap 250 and 4.0 pts more than its Chemicals & Petrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
PCBL Chemical Limited reported FY25 consolidated revenue from operations of ₹8,404.25 crores, up about 31% from ₹6,419.77 crores in FY24, driven mainly by the new Chemical (Aquapharm) segment contributing ₹1,419.81 crores. Standalone revenue grew modestly to ₹5,904.63 crores from ₹5,674.32 crores. However, profitability weakened: consolidated PAT fell to ₹434.67 crores from ₹491.11 crores, and standalone PAT dropped to ₹451.06 crores from ₹533.29 crores, with consolidated net profit margin compressing to 5.20% from 7.69%. The company recognized exceptional items of ₹554.72 crore as goodwill impairment (Aquapharm amalgamation) offset by ₹554.20 crore reversal of deferred tax liability. Finance costs surged sharply (standalone ₹278.16 cr vs ₹126.20 cr), pushing the debt-equity ratio on a consolidated basis to 1.46. An interim dividend of ₹5.50 per share (₹207.60 crores) was paid during Q4.
Higher topline from Aquapharm consolidation is positive, but rising finance costs, margin compression, and weak Q4 standalone earnings (PAT down ~32% YoY) suggest pressure on profitability. Shareholders may see near-term concerns on debt servicing, though the stock could react to the consolidated growth story.